GB202010314D0 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
GB202010314D0
GB202010314D0 GBGB2010314.9A GB202010314A GB202010314D0 GB 202010314 D0 GB202010314 D0 GB 202010314D0 GB 202010314 A GB202010314 A GB 202010314A GB 202010314 D0 GB202010314 D0 GB 202010314D0
Authority
GB
United Kingdom
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2010314.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ILC Therapeutics Ltd
Original Assignee
ILC Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ILC Therapeutics Ltd filed Critical ILC Therapeutics Ltd
Priority to GBGB2010314.9A priority Critical patent/GB202010314D0/en
Publication of GB202010314D0 publication Critical patent/GB202010314D0/en
Priority to PCT/GB2021/051706 priority patent/WO2022008890A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2010314.9A 2020-07-06 2020-07-06 Cancer treatment Ceased GB202010314D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2010314.9A GB202010314D0 (en) 2020-07-06 2020-07-06 Cancer treatment
PCT/GB2021/051706 WO2022008890A1 (en) 2020-07-06 2021-07-05 Cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2010314.9A GB202010314D0 (en) 2020-07-06 2020-07-06 Cancer treatment

Publications (1)

Publication Number Publication Date
GB202010314D0 true GB202010314D0 (en) 2020-08-19

Family

ID=72050433

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2010314.9A Ceased GB202010314D0 (en) 2020-07-06 2020-07-06 Cancer treatment

Country Status (2)

Country Link
GB (1) GB202010314D0 (en)
WO (1) WO2022008890A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201215873D0 (en) 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
CA2998456A1 (en) * 2015-09-15 2017-03-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US20210228687A1 (en) * 2018-06-01 2021-07-29 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases

Also Published As

Publication number Publication date
WO2022008890A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
GB201903546D0 (en) Cancer treatment
IL287652A (en) Cancer treatment
IL307964A (en) Combination therapy for cancer treatment
IL285466A (en) Cancer treatment
IL288035A (en) Cancer treatment
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202118025D0 (en) Cancer treatment
GB202111930D0 (en) Cancer treatment
GB202010314D0 (en) Cancer treatment
GB202303784D0 (en) Cancer treatment
GB202217305D0 (en) Cancer treatment
GB202211123D0 (en) Cancer treatment
GB202210038D0 (en) Cancer treatment
GB202206948D0 (en) Cancer treatment
GB202315849D0 (en) Improved cancer treatment
IL304436A (en) Cancer therapy
GB201910644D0 (en) Cancer Treatment
GB201907149D0 (en) Cancer treatment
GB202001963D0 (en) Cancer therapy
GB202000984D0 (en) Cancer therapy
IL311229A (en) Triple-agent therapy for cancer treatment
GB202108828D0 (en) Novel cancer therapy
GB201918815D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)